Насонова ВА, Барскова ВГ. Ранние диагностика и лечение подагры – научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004;42(1):5–7. https://doi.org/10.14412/1995-4484-2004-1374..
DOI: 10.14412/1995-4484-2004-1374
Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nat Rev Dis Primers. 26;5(1):68. https://doi.org/10.1038/s41572-019-0124-x..
DOI: 10.1038/s41572-019-0124-x
Елисеев МС. Гиперурикемия как фактор поражения почек и мишень терапии. Эффективная фармакотерапия. 2020;16(6):30–35. https://doi.org/10.33978/2307-3586-2020-16-6-30-35..
DOI: 10.33978/2307-3586-2020-16-6-30-35
Dalbeth N, House ME, Aati O, Tan P, Franklin C, Horne A et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74(5):908–911. https://doi.org/10.1136/annrheumdis-2014-20639..
DOI: 10.1136/annrheumdis-2014-20639
Wang S, Pillinger MH, Krasnokutsky S, Barbour KE. The association between asymptomatic hyperuricemia and knee osteoarthritis: data from the third National Health and Nutrition Examination Survey. Osteoarthritis Cartilage. 2019;27(9):1301–1308. https://doi.org/10.1016/j.joca.2019.05.013..
DOI: 10.1016/j.joca.2019.05.013
Braga TT, Forni MF, Correa-Costa M, Ramos RN, Barbuto JA, Branco P et al. Soluble Uric Acid Activates the NLRP3 Inflammasome. Sci Rep. 2017;7:39884. https://doi.org/10.1038/srep39884..
DOI: 10.1038/srep39884
McGill NW, Dieppe PA. Evidence for a promoter of urate crystal formation in gouty synovial fluid. Ann Rheum Dis. 1991;50(8):558–561. https://doi.org/10.1136/ard.50.8.558..
DOI: 10.1136/ard.50.8.558
Meng Y, Horne CR, Samson AL, Dagley LF, Young SN, Sandow JJ et al. Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosis. Nat Commun. 2021;12(1):6783. https://doi.org/10.1038/s41467-021-27032-x..
DOI: 10.1038/s41467-021-27032-x
Насонов ЕЛ. Роль интерлейкина 1 в развитии заболеваний человека. Научно-практическая ревматология. 2018;56(1):19–27. https://doi.org/10.14412/1995-4484-2018-19-27..
DOI: 10.14412/1995-4484-2018-19-27
Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109–115. https://doi.org/10.1002/art.22466..
DOI: 10.1002/art.22466
Cicero AFG, Fogacci F, Giovannini M, Grandi E, Rosticci M, D’Addato S, Borghi C. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Sci Rep. 2018;8(1):11529. https://doi.org/10.1038/s41598-018-29955-w..
DOI: 10.1038/s41598-018-29955-w
Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D et al. Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep. 2013;13(4):550–559. https://doi.org/10.1007/s11892-013-0381-0..
DOI: 10.1007/s11892-013-0381-0
Tsushima Y, Nishizawa H, Tochino Y, Nakatsuji H, Sekimoto R, Nagao H et al. Uric acid secretion from adipose tissue and its increase in obesity. J Biol Chem. 2013;288(38):27138–27149. https://doi.org/:10.1074/jbc.M113.48509..
DOI: :10.1074/jbc.M113.48509
Желябина ОВ, Елисеев МС. Развитие сахарного диабета 2-го типа при подагре. Научно-практическая ревматология. 2021;59(5):599–607. https://doi.org/10.47360/1995-4484-2021-599-607..
DOI: 10.47360/1995-4484-2021-599-607
Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Chiou MJ. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14(2):R83. https://doi.org/10.1186/ar3806..
DOI: 10.1186/ar3806
Елисеев МС, Денисов ИС, Маркелова ЕИ, Глухова СИ, Насонов ЕЛ. Независимые факторы риска развития тяжелых сердечно-сосудистых осложнений у мужчин с подагрой: результаты 7-летнего проспективного исследования. Терапевтический архив. 2017;89(5):10–19. https://doi.org/10.17116/terarkh201789510-19..
DOI: 10.17116/terarkh201789510-19
Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis. 2013;231(1):61–68. https://doi.org/10.1016/j.atherosclerosis.2013.08.023..
DOI: 10.1016/j.atherosclerosis.2013.08.023
Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2014;11(7):1102–1108. https://doi.org/10.1016/j.hrthm.2014.04.003..
DOI: 10.1016/j.hrthm.2014.04.003
Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Semin Arthritis Rheum. 2017;46(4):457–464. https://doi.org/10.1016/j.semarthrit.2016.07.015..
DOI: 10.1016/j.semarthrit.2016.07.015
Елисеев МС. Комментарии к обновленным рекомендациям Американской коллегии ревматологов по лечению подагры. Уратснижающие препараты (часть 1). Современная ревматология. 2020;14(3):117–124. https://doi.org/10.14412/1996-7012-2020-3-117-124..
DOI: 10.14412/1996-7012-2020-3-117-124
Lu N, Rai SK, Terkeltaub R, Kim SC, Menendez ME, Choi HK. Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Semin Arthritis Rheum. 2016;46(2):253–258. https://doi.org/10.1016/j.semarthrit.2016.03.014..
DOI: 10.1016/j.semarthrit.2016.03.014
Kim A, Kim Y, Kim GT, Ahn E, So MW, Lee SG. Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study. Clin Rheumatol. 2020;39(12):3769–3776. https://doi.org/10.1007/s10067-020-05161-w..
DOI: 10.1007/s10067-020-05161-w
Lertnawapan R, Jatuworapruk K. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout. Clin Rheumatol. 2021;40(1):255–262. https://doi.org/10.1007/s10067-020-05262-6..
DOI: 10.1007/s10067-020-05262-6
Chikina M, Sheliabina O, Eliseev M. AB1045 quality of life in patients with gout taking urate-lowering drugs, depending on the achievement of the target level of serum uric acid. Annals of the Rheumatic Diseases. 2022;81:1645–1646. https://doi.org/10.1136/annrheumdis-2022-eular.1766..
DOI: 10.1136/annrheumdis-2022-eular.1766
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200–1210. https://doi.org/10.1056/NEJMoa1710895..
DOI: 10.1056/NEJMoa1710895
Cicero AFG, Cosentino ER, Kuwabara M, Degli Esposti D, Borghi C. Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. Intern Emerg Med. 2019(6):949–956. https://doi.org/10.1007/s11739-019-02070-y..
DOI: 10.1007/s11739-019-02070-y
Konishi M, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y et al. Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. Int J Cardiol. 2022;349:127–133. https://doi.org/10.1016/j.ijcard.2021.11.076..
DOI: 10.1016/j.ijcard.2021.11.076
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J et al. FAST Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745–1757. https://doi.org/10.1016/S0140-6736(20)32234-0..
DOI: 10.1016/S0140-6736(20)32234-0
Pérez Ruiz F, Richette P, Stack AG, Karra Gurunath R, García de Yébenes MJ, Carmona L. Failure to reach uric acid target of < 0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5(2):e001015. https://doi.org/10.1136/rmdopen-2019-001015..
DOI: 10.1136/rmdopen-2019-001015
Barazani SH, Chi WW, Pyzik R, Chang H, Jacobi A, O’Donnell T et al. Quantification of uric acid in vasculature of patients with gout using dual-energy computed tomography. World J Radiol. 2020;12(8):184–194. https://doi.org/10.4329/wjr.v12.i8.184..
DOI: 10.4329/wjr.v12.i8.184
Klauser AS, Halpern EJ, Strobl S, Gruber J, Feuchtner G, Bellmann-Weiler R et al. Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. JAMA Cardiol. 2019;4(10):1019–1028. https://doi.org/10.1001/jamacardio.2019.3201..
DOI: 10.1001/jamacardio.2019.3201
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–2410. https://doi.org/10.1001/jama.283.18.2404..
DOI: 10.1001/jama.283.18.2404
Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234–1242. https://pubmed.ncbi.nlm.nih.gov/20486275.https://pubmed.ncbi.nlm.nih.gov/20486275
Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234–1242. https://pubmed.ncbi.nlm.nih.gov/20486275.https://pubmed.ncbi.nlm.nih.gov/20486275
Желябина ОВ, Елисеев МС, Глухова СИ, Насонов ЕЛ. Факторы, влияющие на развитие сахарного диабета 2-го типа у пациентов с подагрой (результаты многолетнего проспективного исследования). Научно-практическая ревматология. 2022;60(3):374–380. https://doi.org/10.47360/1995-4484-2022-374-380..
DOI: 10.47360/1995-4484-2022-374-380
Choi S, Voskanian N, Ramos J, Nguyen KHY. Tophaceous Gout in the Pancreas: Case Reports and Review of the Literature. Case Rep Rheumatol. 2022;2022:3671627. https://doi.org/10.1155/2022/3671627..
DOI: 10.1155/2022/3671627
Елисеев МС, Новикова АМ. Коморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапии. Терапевтический архив. 2019;91(5):120–128. https://doi.org/10.26442/00403660.2019.05.000232..
DOI: 10.26442/00403660.2019.05.000232
Schumacher HRJr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540–1548. https://doi.org/10.1002/art.24209..
DOI: 10.1002/art.24209
Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin Rheumatol. 2014;33(11):1643–1648. https://doi.org/10.1007/s10067-014-2745-5..
DOI: 10.1007/s10067-014-2745-5
Елисеев МС, Желябина ОВ, Чикина МН, Тхакоков ММ. Эффективность фебуксостата у пациентов с подагрой в зависимости от функции почек. РМЖ. 2022;6(3):140–147. https://doi.org/10.32364/2587-6821-2022-6-3-140-147..
DOI: 10.32364/2587-6821-2022-6-3-140-147
Елисеев МС, Чикина МН, Желябина ОВ. Влияние фебуксостата на вероятность достижения целевого уровня мочевой кислоты в сыворотке крови и почечную функцию у пациентов с подагрой: результаты проспективного наблюдательного исследования. Эффективная фармакотерапия. 2023;19(29):16–21. https://doi.org/10.33978/2307-3586-2023-19-29-16-21..
DOI: 10.33978/2307-3586-2023-19-29-16-21
Liu X, Qiu Y, Li D, Tan J, Liang X, Qin W. Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021;12:690557. https://doi.org/10.3389/fphar.2021.690557..
DOI: 10.3389/fphar.2021.690557
Pascual E, Addadi L, Andrés M, Sivera F. Mechanisms of crystal formation in gout-a structural approach. Nat Rev Rheumatol. 2015;11(12):725–730. https://doi.org/10.1038/nrrheum.2015.125..
DOI: 10.1038/nrrheum.2015.125
Черёмушкина ЕВ, Елисеев МС. Гиперурикемия и подагра: влияние на костный метаболизм и суставной хрящ (обзор литературы). Ожирение и метаболизм. 2022;19(3):348–357. https://doi.org/10.14341/omet12894..
DOI: 10.14341/omet12894
Aibibula Z, Ailixiding M, Iwata M, Piao J, Hara Y, Okawa A, Asou Y. Xanthine oxidoreductase activation is implicated in the onset of metabolic arthritis. Biochem Biophys Res Commun. 2016;472(1):26–32. https://doi.org/10.1016/j.bbrc.2016.02.039..
DOI: 10.1016/j.bbrc.2016.02.039